A1,
A2,
B,
C1,
C2,
D,
E,
F,
G-H,
I-K,
L,
M,
N,
O,
P1,
P2,
Q-R,
S,
T,
U-V,
W-Z
Cogentin Indications, Dosage, Storage, Stability - Benztropine
Cogentin Indications, Dosage, Storage, Stability - Benztropine
INDICATIONS
For use as an adjunct in
the therapy of all forms of
parkinsonism. Useful also in the control
of extrapyramidal disorders
(except tardive dyskinesia
- see PRECAUTIONS) due to neuroleptic
drugs (e.g. phenothiazines).
DOSAGE AND ADMINISTRATION
Benztropine mesylate tablets should be used when patients are able to
take oral medication. The injection
is especially useful for psychotic patients with acute
dystonic reactions or other
reactions that make oral medication difficult or impossible. It is recommended
also when a more rapid response
is desired than can be obtained with the tablets. Because of cumulative
action, therapy should be
initiated with a low dose which
is increased gradually at five or six-day intervals to the smallest amount
necessary for optimal relief. Increases should be made in increments of
0.5 mg to a maximum
of 6 mg or until optimal results
are obtained without excessive adverse reactions.
Postencephalitic and Idiopathic
Parkinsonism - The usual daily dose
is 1 to 2 mg with a range
of 0.5 to 6 mg orally or parenterally.
As with any agent used in parkinsonism,
dosage must be individualized
according to age and weight, and
the type of parkinsonism
being treated. Generally, older patients, and thin patients cannot tolerate
large doses. Most patients with postencephalitic parkinsonism
need fairly large doses and tolerate
them well. Patients with a p.o.
mental outlook are usually
poor candidates for therapy.
In idiopathic parkinsonism,
therapy may be initiated with
a single daily dose of 0.5 to 1 mg
at bedtime.
In some patients, this will
be adequate; in others 4 to 6 mg
a day may be required. In postencephalitic
parkinsonism, therapy may
be initiated in most patients with 2 mg
a day in one or more doses. In
highly sensitive patients, therapy
may be initiated with 0.5 mg at
bedtime, and increased as necessary. Some patients experience
greatest relief by taking the
entire dose at bedtime, others react
m o r e favorably to divided doses, two to four times a day. Frequently,
one dose a day is sufficient
and divided doses may be unnecessary or undesirable.
The long duration of action
of this drug makes it particularly
suitable for bedtime medication
when its effects may last throughout the night, enabling patients to turn
in bed during the night more easily,
and to rise in the morning. When benztropine is started, do not terminate
therapy with other antiparkinsonian
agents abruptly. If the other agents are to be reduced or discontinued,
it must be done gradually. Many patients obtain greatest relief with combination
therapy. Benztropine Mesylate may be used concomitantly with carbidopa
levodopa, or with levodopa, i n which case
periodic dosage adjustment
may be required in order to
maintain optimum response.
Drug-Induced Extrapyramidal Disorders
In treating extrapyramidal disorders
due to neuroleptic drugs
(e.g., phenothiazines). the recommended dosage is 1 to 4 mg
once or twice a day orally or parenterally. Dosage must be individualized
according to the need of the
patient. Some patients require more than recommended; others do not need
as much. In acute
dystonrc reactions 1 to 2 mL of the injection
usually relieves the condition
quickly. After that, the tablets. 1 to 2 mg
twice a day, usually prevent recurrence. When extrapyramidal
disorders develop soon after initiation of treatment with neuroleptic
drugs (e.g., phenothiazines), they are likely to be transient. One to
2 mg of benztropine mesylate tablets
two or three times a day usually provides relief
within one or two days. After one or two weeks, the drug should be withdrawn
to determine the continued need
for it. If such disorders recur, benztropine can be reinstituted. Certain
drug-induced extrapyramidal disorders that develop slowly may not respond
to benztropine.
HOW SUPPLIED
Benztropine Mesylate Tablets, USP 0.5 mg
- Each white, round, compressed tablet is scored and engraved with identification
logo INV and 208 on one side.
NDC 62269- 208- 24 in bottles of 100 tablets
NDC 62269- 208- 29 in bottles of 500 tablets
NDC 62269- 208- 30 in bottles of 1000 tablets
Benztropine Mesylate Tablets, USP, 1 mg
- Each white, oval shaped, compressed
tablet is scored and engraved with identification
logo INV and 209 on one side.
NDC 62269- 209- 24 in bottles of 100 tablets
NDC 62269- 209- 29 in bottles of 500 tablets
NDC 62269- 209- 30 in bottles of 1000 tablets
Benztropine Mesyiate Tablets, USP, 2 mg
- Each white, round, compressed tablet is scored and engraved with identification
logo INV and 210 on one side.
NDC 62269- 210- 24 in bottles of 100 tablets
NDC 62269- 210- 29 in bottles of 500 tablets
NDC 62269- 210- 30 in bottles of 1000 tablets
Dispense in a well- closed container.
Store at controlled room temperature
15°- 30° C (59°- 86°F)
CAUTION: Federal Law prohtbits dispensing without prescription.
top
